MRSN logo

MRSN
Mersana Therapeutics Inc

2,942
Mkt Cap
$44.27M
Volume
1.28M
52W High
$70.73
52W Low
$5.21
PE Ratio
-0.59
MRSN Fundamentals
Price
$27.20
Prev Close
$8.87
Open
$27.69
50D MA
$8.51
Beta
2.06
Avg. Volume
64,039.48
EPS (Annual)
-$14.12
P/B
-0.83
Rev/Employee
$397,029.41
Loading...
Loading...
News
all
press releases
MRSN Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Mersana Therapeutics, Inc. is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Mersana Therapeutics, Inc. (NASDAQ: MRSN) to Day One Biopharmaceuticals, Inc. is fair to Mersana shareholders...
Business Wire·1h ago
News Placeholder
More News
News Placeholder
Mersana Therapeutics To Be Acquired By Day One Biopharmaceuticals For Up To $285 Mln
(RTTNews) - Mersana Therapeutics, Inc. (MRSN), a biopharmaceutical company, Thursday, announced that it has entered a definitive agreement to be acquired by Day One Biopharmaceuticals through a...
Nasdaq News: Markets·3h ago
News Placeholder
MRSN Stock Soars Over 200% Pre-Market After Day One Acquisition Deal
The upfront purchase price of $25 alone represents a premium of 182% from Mersana’s closing price on Wednesday.
Stocktwits·3h ago
News Placeholder
Cue Biopharma, Inc. (CUE) Reports Q3 Loss, Lags Revenue Estimates
Cue Biopharma (CUE) delivered earnings and revenue surprises of +30.00% and -14.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·16h ago
News Placeholder
Curis (CRIS) Reports Q3 Loss, Beats Revenue Estimates
Curis (CRIS) delivered earnings and revenue surprises of +20.97% and +8.58%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·7d ago
News Placeholder
Royalty Pharma (RPRX) Beats Q3 Earnings and Revenue Estimates
Royalty Pharma (RPRX) delivered earnings and revenue surprises of +5.41% and +1.34%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·8d ago
News Placeholder
Wall Street Analysts See a 314.81% Upside in Mersana Therapeutics (MRSN): Can the Stock Really Move This High?
The mean of analysts' price targets for Mersana Therapeutics (MRSN) points to a 314.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks·2mo ago
News Placeholder
Wall Street Analysts Think Mersana Therapeutics (MRSN) Could Surge 248.83%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 248.8% in Mersana Therapeutics (MRSN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·3mo ago
News Placeholder
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Lags Revenue Estimates
Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of -8.80% and -58.90%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates
Stoke Therapeutics (STOK) delivered earnings and revenue surprises of +29.82% and +181.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago

Latest MRSN News

View

Advertisement|Remove ads.

Advertisement|Remove ads.